Chong Kun Dang Pharmaceutical Corp (CKD Pharma) is a manufacturer of pharmaceutical products. The company’s product portfolio includes prescription products, over the counter (OTC) products, quasi drugs, health supplements and consumer health products.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company’s R&D activities focus on developing novel medicines for treating various diseases. CKD Pharma carries out its R&D activities at its Hyo-Jong Research Institute in Gyeonggi, Korea. The company’s research institute operates three independent laboratories, namely, The New Drug Discovery lab for identifying novel drugs; The Technology Development Lab for discovering generic drugs, active pharmaceutical ingredients, and botanical drugs; and The Bio Research Lab for developing antibodies, vaccines, and recombinant proteins. The company assigned a total of 563 employees for research and development. In FY2022, the company spent KRW176,324.875 million on R&D activities which contributes 11.8% of total revenue. The company also operates a manufacturing facility in Cheonan City, Chungcheongnam, Korea.